Matthew Biegler

Edward Tenthoff

Joseph Schwartz

Anish Nikhanj

Corinne Jenkins

Dae Gon Ha

Gregory Renza

Kristen Kluska

Rick Miller

Drewry Park

Jeremiah Lorentz

- Fulcrum Therapeutics, Inc. reported positive results from the **12 mg Cohort 3b** of its PIONEER Phase 1b study for **pociredir** in Sickle Cell Disease, demonstrating a mean **8.6% absolute increase in fetal hemoglobin (HbF)** and a **0.9 g/dL mean increase in hemoglobin (Hb)** at 12 weeks, alongside encouraging trends in vaso-occlusive crisis (VOC) reduction.  **[1680581_0001193125-25-190746_fulc-ex99_1.htm:5]** **[1680581_0001193125-25-190746_fulc-ex99_1.htm:6]** **[1680581_0001193125-25-190746_fulc-ex99_1.htm:7]** 
- The company expects to release **20 mg cohort data by the end of 2025** and plans an **End of Phase 1 meeting with the FDA in early 2026** to discuss the next study.  **[1680581_0001193125-25-190746_fulc-ex99_1.htm:7]** 
- As of **June 30, 2025**, Fulcrum Therapeutics, Inc. had a cash position of **$214.1 million**, which is projected to provide a cash runway into **2028**.  **[1680581_0001193125-25-190746_fulc-ex99_1.htm:2]** **[1680581_0001193125-25-190746_fulc-ex99_1.htm:7]**

Fulcrum Therapeutics, Inc. Provides Clinical Trial Update and Financial Position

Fulcrum Therapeutics (FULC)